Puma Biotechnology (PBYI) Cash & Current Investments (2011 - 2026)

Puma Biotechnology's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $38.3 million for Q1 2026.

• Quarterly Cash & Current Investments fell 58.91% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.3 million (down 58.91% YoY) and the FY2025 annual result came in at $31.7 million, down 68.58% from the prior year.
• Cash & Current Investments was $38.3 million for Q1 2026 at Puma Biotechnology, up from $31.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $107.2 million in Q1 2024 and bottomed at $31.7 million in Q4 2025.
• A 5-year average of $78.0 million and a median of $81.1 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 50.47% — and 2025, when it slumped 68.58%.
• Puma Biotechnology's Cash & Current Investments stood at $81.1 million in 2022, then advanced by 18.34% to $95.9 million in 2023, then advanced by 5.24% to $101.0 million in 2024, then slumped by 68.58% to $31.7 million in 2025, then increased by 20.67% to $38.3 million in 2026.
• Business Quant data shows PBYI's Cash & Current Investments at $38.3 million in Q1 2026, $31.7 million in Q4 2025, and $94.4 million in Q3 2025.